Ginseng peptide as well as preparation method and application thereof
By extracting specific ginseng peptides from fermented ginseng filter residues and preparing fermented ginseng hydrolysates, the problems of ginseng residue utilization and osteoporosis treatment are solved, and the symptoms and bone density of osteoporosis are safely and effectively improved, and resource waste and environment are reduced. pollute.
Patent Information
- Application Number
- CN202411308704.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-09-19
AI Technical Summary
The prior art has failed to effectively utilize ginseng residues, and traditional osteoporosis treatment drugs have side effects, and lack safe and effective treatment strategies.
By treating the fermented ginseng filter residue, ginseng peptides containing specific amino acid sequences are extracted and identified to prepare fermented ginseng hydrolysate, which is used to inhibit the differentiation of bone marrow mononuclear cells into osteoclasts and improve osteoporosis.
Fermented ginseng hydrolysates significantly increase resistance to osteoporosis, improve bone density, reduce trabecular space, enhance movement motivation, prevent fractures, and are safe and long-term use without side effects.
Smart Images

Figure CN119080873A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a ginseng peptide and a preparation method and application thereof. Background Art
[0002] Ginseng (Panax ginseng CAMeyer) is a perennial herbaceous plant belonging to the genus Panax L. of the Araliaceae family. It is also known as the "king of herbs" and has a long history of application. It is one of the most valuable medicinal plants in traditional medicine. Since ginseng was included in the list of new resource foods in 2012, its application scope has been continuously expanded and its demand has been increasing. Ginseng processing technology is becoming increasingly diversified. In addition to traditional decoction, industrial extraction, microbial fermentation and other technologies will produce a large amount of ginseng residues. At present, the main way to utilize ginseng residues is as organic fertilizer and animal feed, or directly discharged into the environment. The resource utilization rate has not been maximized. At present, there is still a lack of means to recycle ginseng residues with high added value and high economic returns.
[0003] Osteoporosis is a common bone metabolic disease, accompanied by pathological changes such as osteopenia and abnormal bone tissue microstructure, which can eventually lead to thinning, brittle and easy fracture of bones, and is more common in middle-aged and elderly people. The disease is caused by the rate of bone resorption exceeding the rate of bone formation. This imbalance may be caused by factors such as changes in hormone levels, malnutrition, lack of exercise, smoking, excessive drinking and drug use. It is usually asymptomatic in the early stage and is not discovered until complications such as fractures or physical deformities occur, which seriously affects the quality of life. Treatment strategies include promoting bone formation and inhibiting bone resorption. Commonly used drugs include calcium, vitamin D, growth hormone, glucocorticoid antagonists, calmodulin, bisphosphonates, estrogen and RANKL inhibitors. These drugs are usually used in combination to improve the efficacy, but long-term use may cause side effects such as hypercalcemia, vascular sclerosis, kidney stones, diabetes, joint pain, gastrointestinal discomfort, skeletal muscle pain and other problems. Therefore, the development of new safe and effective treatment strategies is very important for patients with osteoporosis. Summary of the invention
[0004] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a ginseng peptide and a preparation method and application thereof.
[0005] To achieve the above object, the technical solution adopted by the present invention is:
[0006] In a first aspect, the present invention provides a ginseng peptide, comprising a characteristic peptide having an amino acid sequence of at least one of Leu-Tyr, Met-Met, Leu-Arg, Leu-Ala-Arg, Ser-Ala-Leu-Ala-Phe-Arg, Arg-Leu-Asp-Phe-Arg, Leu-Leu-Leu-Leu-Gly-His, Leu-Leu-Leu-Leu-Leu-Gly-His and Ala-Pro.
[0007] The invention obtains ginseng peptides by treating fermented ginseng residues, and identifies the ginseng peptides containing characteristic peptides with amino acid sequences of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG by HPLC-MS / MS.
[0008] As a preferred embodiment of the ginseng peptide of the present invention, the ginseng peptide includes a characteristic peptide with an amino acid sequence of Leu-Tyr, a characteristic peptide of Met-Met, a characteristic peptide of Leu-Arg, a characteristic peptide of Leu-Ala-Arg, a characteristic peptide of Ser-Ala-Leu-Ala-Phe-Arg, a characteristic peptide of Arg-Leu-Asp-Phe-Arg, a characteristic peptide of Leu-Leu-Leu-Leu-Gly-His, a characteristic peptide of Leu-Leu-Leu-Leu-Leu-His-Gly and a characteristic peptide of Ala-Pro.
[0009] In a second aspect, the present invention provides a fermented ginseng hydrolyzate, comprising the above-mentioned ginseng peptide.
[0010] As a preferred embodiment of the fermented ginseng hydrolyzate of the present invention, the mass ratio of the characteristic peptide Leu-Tyr, characteristic peptide Met-Met, characteristic peptide Leu-Arg, characteristic peptide Leu-Ala-Arg, characteristic peptide Ser-Ala-Leu-Ala-Phe-Arg, characteristic peptide Arg-Leu-Asp-Phe-Arg, characteristic peptide Leu-Leu-Leu-Leu-Gly-His, characteristic peptide Leu-Leu-Leu-Leu-Leu-His-Gly and characteristic peptide Ala-Pro of ginseng peptides in the fermented ginseng hydrolyzate is Leu-Tyr:Met-Met. et:Leu-Arg:Leu-Ala-Arg:Ser-Ala-Leu-Ala-Phe-Arg:Arg-Leu-Asp-Phe-Arg:Leu-Leu-Leu-Leu-Gly-His:Leu-Leu-Leu-Leu-Leu -Gly-His: Ala-Pro=(49.6-52.1): (6.3-7.6): (7.5-8.8): (1.5-1.8): (18.1-19.5): (2.6-3.1): (1.4-1.6): (1.2-1.5): (7.8-8.0).
[0011] As a preferred embodiment of the fermented ginseng hydrolyzate of the present invention, the characteristic peptide Leu-Tyr, characteristic peptide Met-Met, characteristic peptide Leu-Arg, characteristic peptide Leu-Ala-Arg, characteristic peptide Ser-Ala-Leu-Ala-Phe-Arg, characteristic peptide Arg-Leu-Asp-Phe-Arg, characteristic peptide Leu-Leu-Leu-Leu-Gly-His, characteristic peptide Leu-Leu-Leu-Leu-Leu-His-Gly and The mass ratio of the characteristic peptide Ala-Pro is Leu-Tyr: Met-Met: Leu-Arg: Leu-Ala-Arg: Ser-Ala-Leu-Ala-Phe-Arg: Arg-Leu-Asp-Phe-Arg: L eu-Leu-Leu-Leu-Gly-His: Leu-Leu-Leu-Leu-Leu-Gly-His: Ala-Pro=49.6:7.6:8.8:1.5:19.5:2.6:1.4:1.2:7.8.
[0012] In a third aspect, the present invention provides a method for preparing the fermented ginseng hydrolysate, comprising the following steps:
[0013] (1) mixing the fermented ginseng residue with water, adjusting the pH to 7.0-8.0, extracting at 45-55° C. for 30-40 min, adding protease, bathing at 45-55° C. for 4-5 h, centrifuging, and obtaining an enzymatic solution;
[0014] (2) Drying the enzymatic hydrolyzate obtained in step (2) to obtain a fermented ginseng hydrolyzate containing ginseng peptides.
[0015] The present invention obtains fermented ginseng hydrolyzate by leaching and enzymolysis of fermented ginseng residue, and concentrates and dries the fermented ginseng hydrolyzate to prepare fermented ginseng hydrolyzate containing ginseng peptides. In vivo and in vitro experiments have verified that the fermented ginseng hydrolyzate has excellent efficacy in inhibiting the differentiation of bone marrow mononuclear cells into osteoclasts, and can improve osteoporosis caused by hormones.
[0016] As a preferred embodiment of the preparation method of the present invention, in step (1), the ratio of the fermented ginseng residue to water is fermented ginseng residue: water = 1 g: (25-30) mL.
[0017] As a preferred embodiment of the preparation method of the present invention, in step (2), the type of protease includes at least one of papain, trypsin and alkaline protease.
[0018] As a preferred embodiment of the preparation method of the present invention, in step (2), the amount of the protease added is 0.75-0.80 mg of protease per 1 g of fermented ginseng residue, and the concentration of the protease is 1350-1400 U / mg.
[0019] As a preferred embodiment of the preparation method of the present invention, in step (1), the fermented ginseng residue is obtained by centrifuging and filtering ginseng after microbial fermentation.
[0020] In a fourth aspect, the present invention provides the use of the above-mentioned ginseng peptides or fermented ginseng hydrolysate in the preparation of products for improving osteoporosis and its complications.
[0021] In vivo and in vitro experiments have confirmed that the ginseng peptides and fermented ginseng hydrolysates provided by the present invention can significantly increase resistance to osteoporosis.
[0022] In a fifth aspect, the present invention provides the use of the above-mentioned ginseng peptides or fermented ginseng hydrolysate in the preparation of products for preventing osteoporosis and its complications.
[0023] As a preferred embodiment of the application of the present invention, the products include medicines, foods, health products, cosmetics and biological products.
[0024] As a preferred embodiment of the application of the present invention, the dosage of the fermented ginseng hydrolyzate is 250-1000 mg per 1 kg body weight of the organism.
[0025] As a preferred embodiment of the application of the present invention, the osteoporosis includes primary osteoporosis, secondary osteoporosis, idiopathic osteoporosis and regional osteoporosis. The primary osteoporosis is postmenopausal osteoporosis and senile osteoporosis; the secondary osteoporosis is osteoporosis stimulated by endocrine diseases (hyperparathyroidism, Cushing's syndrome, diabetes), chronic diseases (chronic kidney disease, liver disease, chronic obstructive pulmonary disease), drug use (glucocorticoids, antiepileptic drugs, anticoagulants), and lifestyle (long-term alcoholism, smoking, malnutrition, lack of exercise); the idiopathic osteoporosis is of unknown cause, usually occurs in young people or children, and has no clear secondary cause; the regional osteoporosis is caused by local ischemia, trauma, infection or nervous system lesions.
[0026] As a preferred embodiment of the application of the present invention, the improvement effect of the ginseng peptides and fermented ginseng hydrolyzate on osteoporosis is manifested in relieving bone pain and back pain, correcting hunchback and body shape changes, enhancing exercise motivation, and preventing fractures and disabilities.
[0027] As a preferred embodiment of the application of the present invention, the improvement effects of the ginseng peptides and fermented ginseng hydrolysate on osteoporosis are manifested in the following aspects: increasing bone density, reducing trabecular spacing, increasing the number of trabecular connections, reducing trabecular fractures, and improving bone mineralization.
[0028] As a preferred embodiment of the application of the present invention, the improvement effect of the ginseng peptides and fermented ginseng hydrolysates on osteoporosis is also reflected in inhibiting the differentiation of osteoclasts and reducing the levels of osteoclast markers, including but not limited to serum calcium, serum phosphorus, serum 25-hydroxyvitamin D, serum alkaline phosphatase, and serum PTH.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] 1. The present invention obtains ginseng peptides by treating fermented ginseng residue, and identifies the ginseng peptides by HPLC-MS / MS, which contain characteristic peptides with amino acid sequences of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG.
[0031] 2. The present invention has experimentally confirmed that ginseng peptides and fermented ginseng hydrolyzate containing ginseng peptides have excellent efficacy in inhibiting the differentiation of bone marrow mononuclear cells into osteoclasts, can improve hormone-induced osteoporosis, and have the advantages of safety, long-term use, and no side effects. They can be applied to products for improving osteoporosis and its related symptoms, and have broad application prospects and economic value.
[0032] 3. The ginseng peptides and fermented ginseng hydrolysates provided by the present invention have a small molecular weight and are easily absorbed, and have fewer application restrictions on elderly osteoporosis patients with poor gastrointestinal function.
[0033] 4. The fermented ginseng hydrolyzate of the present invention is derived from ginseng residue after microbial fermentation, which can improve the utilization rate of ginseng and reduce resource waste and environmental pollution. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 This is the liquid quality BPC diagram of the fermented ginseng hydrolyzate in Example 1 of the present invention;
[0035] Figure 2 The secondary mass spectrum of the LY peptide segment in Example 1 of the present invention;
[0036] Figure 3 The secondary mass spectrum of the MM peptide segment in Example 1 of the present invention;
[0037] Figure 4 The secondary mass spectrum of the LR peptide segment in Example 1 of the present invention;
[0038] Figure 5 The secondary mass spectrum of the LAR peptide segment in Example 1 of the present invention;
[0039] Figure 6 The secondary mass spectrum of the SALAFR peptide segment in Example 1 of the present invention;
[0040] Figure 7 The secondary mass spectrum of the RLDFR peptide segment in Example 1 of the present invention;
[0041] Figure 8 The secondary mass spectrum of the LLLLGH peptide segment in Example 1 of the present invention;
[0042] Fig. 9 This is the secondary mass spectrum of the LLLLLHG peptide segment in Effect Example 1 of the present invention;
[0043] Fig.10 This is the secondary mass spectrum of the AP peptide segment in Effect Example 1 of the present invention. DETAILED DESCRIPTION
[0044] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.
[0045] Unless otherwise specified, other materials, reagents, etc. used in the examples can be obtained from commercial sources.
[0046] The ginseng species used in the ginseng peptides and fermented ginseng hydrolysates of the present invention are not limited. The fermented ginseng residue used in the following examples and comparative examples is prepared by subjecting ginseng to microbial fermentation according to the method of Example 1 in the technology disclosed in CN 116334147 A, followed by centrifugal filtration after the fermentation is completed.
[0047] SPF female C57BL / 6 mice were purchased from Guangdong Medical Experimental Animal Center (SCXK (Yue) 2022-0002).
[0048] The techniques not described in detail in the following embodiments, comparative examples and effect examples are all commonly used techniques in the art. Please refer to "Molecular Biology Experiment Manual" (Ma Wenli, People's Military Medical Publishing House), "Molecular Biology Experiment (Second Edition)" (Zhejiang University Press), and "Cell Biology Experiment" (Yang Hongbing, Hou Lixia, Zhang Yuxi, Higher Education Press).
[0049] In the following embodiments and effect examples, "V" refers to valine (Val), "P" refers to proline (Pro), "G" refers to glycine (Gly), "H" refers to histidine (His), "R" refers to arginine (Arg), "K" refers to lysine (Lys), "I" refers to isoleucine (Ile), "F" refers to phenylalanine (Phe), "L" refers to leucine (Leu), "W" refers to tryptophan (Trp), "A" refers to alanine (Ala), "M" refers to methionine (Met), "C" refers to cysteine (Cys), "N" refers to asparagine (Asn), "S" refers to serine (Ser), "Q" refers to glutamine (Gln), "Y" refers to tyrosine (Tyr), "D" refers to aspartic acid (Asp), "E" refers to glutamic acid (Glu), and "T" refers to threonine (Thr).
[0050] In the following embodiments, comparative examples and effect examples, LY refers to the Leu-Tyr characteristic peptide, MM refers to the Met-Met characteristic peptide, LR refers to the Leu-Arg characteristic peptide, LAR refers to the Leu-Ala-Arg characteristic peptide, SALAFR refers to the Ser-Ala-Leu-Ala-Phe-Arg characteristic, RLDFR refers to the Arg-Leu-Asp-Phe-Arg characteristic peptide, LLLLGH refers to the Leu-Leu-Leu-Leu-Gly-His characteristic peptide, LLLLLHG refers to the Leu-Leu-Leu-Leu-Leu-His-Gly characteristic peptide, and AP refers to the Ala-Pro characteristic peptide. The amino acid sequences of the above characteristic peptides are shown in SEQ ID NO.1-9.
[0051] Example 1
[0052] This embodiment provides a fermented ginseng hydrolyzate and a preparation method thereof, the preparation method comprising the following steps:
[0053] S1. Mix the fermented ginseng residue with water at a solid-liquid ratio of 1 g:30 mL, adjust the pH to 8.0 with 2M NaOH solution, extract at 50°C for 30 min, add 0.00075 g of trypsin (concentration of 1350 U / mg) per 1 g of fermented ginseng residue, perform enzymolysis at 50°C for 5 h, water bath at 85°C for 30 min, cool to room temperature, centrifuge at 10000 rpm for 10 min, collect the supernatant, and obtain an enzymolysis solution;
[0054] S2. The enzymatic hydrolyzate obtained in step S1 is concentrated under reduced pressure at 65° C. and −0.09 MPa, and freeze-dried to obtain a fermented ginseng hydrolyzate.
[0055] Effect Example 1
[0056] The ginseng obtained in Example 1, the fermented ginseng residue and the fermented ginseng hydrolyzate were characterized as follows:
[0057] 1. Determination of ginsenosides
[0058] Determination of ginsenosides in ginseng, fermented ginseng residue and fermented ginseng peptides by HPLC. Waters UPLC liquid chromatograph, chromatographic column: Waters XBridge BEH Shield C18 2.1mm×100mm×1.7μm, column temperature: 40℃, detection wavelength: 203nm, flow rate: 0.6mL / min, injection volume: 2μL, mobile phase consists of water (A) and acetonitrile (B), elution method: 0-0.5min 15% B, 40.5-14.5min15-30% B, 14.5-15.5min 30-32% B, 15.5-18.5min 32-38% B, 18.5-24.0min 38-43% B, 24.0-27.0min 43.0-55.0% B, 27.0-31.0min, 55% B, 31.0-35.0min, 55-70% B, 35.0-38.0min, 70-90% B.
[0059] Preparation of reference solution: Weigh 10.35 mg of ginsenoside Rg1, 10.25 mg of ginsenoside Re, 10.08 mg of ginsenoside Rb1, 10.07 mg of ginsenoside Rd, 10.70 mg of ginsenoside Rc and 10.02 mg of ginsenoside Rb2 respectively, add appropriate amount of methanol to dissolve and make the volume to 5 mL, then shake well; add appropriate amount of methanol to dissolve 3.16 mg of ginsenoside Rf to make the volume to 1.5 mL, then shake well. Accurately pipette 1 mL of the above solution into a 20 mL volumetric flask, dilute to the mark with methanol and shake well to obtain reference solutions with ginsenoside Rg1 concentrations of 103.5 μg / mL, ginsenoside Re concentrations of 102.5 μg / mL, ginsenoside Rb1 concentrations of 100.8 μg / mL, ginsenoside Rd concentrations of 100.7 μg / mL, ginsenoside Rf concentrations of 105.35 μg / mL, ginsenoside Rc concentrations of 107.0 μg / mL, and ginsenoside Rb2 concentrations of 100.2 μg / mL.
[0060] Preparation of sample solution: Take about 1g each of ginseng powder (passed through No. 4 sieve), fermented ginseng residue, and fermented ginseng peptide, accurately weigh, place in a 20mL volumetric flask, add appropriate amount of methanol, treat with ultrasound (500W, 37kHz) for 30min, take out, leave overnight, ultrasound (500W, 37kHz) for 30min, cool and add methanol to the scale, shake well, filter with 0.22μm organic filter membrane, and take the filtrate to obtain.
[0061] Table 1. Ginsenoside test results
[0062]
[0063] As can be seen from Table 1, the ginsenoside content in the fermented ginseng hydrolysate is much lower than that of the ginseng before fermentation. The total saponin content is only 25.8% of that before fermentation, and ginsenosides Rg1 and Re are not detected, indicating that after fermentation, ginsenosides are almost transferred to the fermentation liquid, while the ginsenoside content in the fermented ginseng residue and fermented ginseng hydrolysate is very low.
[0064] 2. Determination of amino acid composition in fermented ginseng hydrolysate.
[0065] Referring to the national safety standard GB 5009.124-2016 for the determination of amino acids in food, the fermented ginseng hydrolyzate prepared in Example 1 was analyzed for amino acid content using an S7130 amino acid fully automatic analyzer (SYKAM, Germany), with a separation column of Cation Separation Column LCA K06 / Na, 150 mm × 4.6 mm; and an ammonia removal column of Ammonia Filtration Column LCA K04 / Na, 100 mm × 4.6 mm. The results are shown in Table 2. The principle of the determination is that the protein in the food is hydrolyzed by hydrochloric acid to form free amino acids, which are separated by the ion exchange column of the amino acid analyzer and then react with the ninhydrin solution to produce a color reaction, which is detected at its maximum absorption peak wavelength of 570 nm and 440 nm, and the amino acid composition of the fermented ginseng peptide is obtained based on the retention time and peak area.
[0066] Table 2 Amino acid content of fermented ginseng hydrolysate
[0067]
[0068] As shown in Table 2, aspartic acid, arginine, etc. are the main amino acids in the fermented ginseng hydrolysate, followed by glutamic acid and leucine, indicating that the content of acidic amino acids is relatively high. The fermented ginseng residue is acidic under natural conditions, and the alkaline dissolution method can effectively extract the protein in the fermented ginseng residue.
[0069] 3. The peptide sequence of the fermented ginseng hydrolysate obtained in Example 1 was identified.
[0070] The amino acid sequence of the fermented ginseng hydrolysate prepared in Example 1 was identified using the HPLC-MS / MS method. The specific detection method is as follows:
[0071] The samples were separated and detected using an X500 LC-ESI-Q-TOF high-resolution liquid chromatography-mass spectrometer (AB SCIEX, USA). The liquid chromatography and mass spectrometry control software used was SCIEX OS2.0 integrated version (AB SCIEX, USA); the chromatographic column used was 1×100mm HSS T3 (1.8μm, Waters, USA).
[0072] The mobile phase consisted of 0.1% (v / v) formic acid aqueous solution (A) and acetonitrile (B), and the elution method was: 0-4.00min5.0% B, 4.00-6.00min5.0-10.0% B, 6.00-30.00min10.0-40.0% B, 30.00-34.00min40.0-90.0% B, 34.00-40.00min90% B, 40.00-42.00min90.0-5.0% B, 42.00-52.00min5.0% B, flow rate 0.05mL / min, injection volume 1μL, column temperature 40°C, the percentages of the above mobile phases mean volume percentages, volume of mobile phase B / total volume of mobile phase A and mobile phase B.
[0073] Mass spectrometry detection method: scanning cycle 0.642s, ESI ion source temperature 500℃, positive ion mode, spray voltage 5500V, TOF primary scanning range 100-1200Da, secondary scanning range 50-1200Da, working mode IDA, maximum candidate ion number 4, dynamic exclusion turned on, and the rest of the parameters used the default values of the proteomics method. Note that the dead volume should be minimized before using the instrument. The identification results are shown in Figure 1-10 and Table 3.
[0074] Table 3 Identification results of characteristic peptide sequences in fermented ginseng hydrolysate
[0075]
[0076]
[0077] like Figure 1-10 As shown in Table 3, the present invention uses HPLC-MS / MS technology to identify 9 characteristic amino acid sequences from fermented ginseng hydrolysate, including 4 dipeptides (LY, MM, LR, AP), 1 tripeptide (LAR), 1 pentapeptide (RLDFR), 2 hexapeptides (SALAFR, LLLLGH), and 1 7-peptide (LLLLLHG), which can be used as quality control standards for the enzymatic fermentation ginseng peptides.
[0078] Effect Example 2
[0079] Tartrate-resistant acid phosphatase (TRAP) exists in many cells, but it will abnormally aggregate during bone resorption, be secreted by osteoclasts, participate in the degradation and remodeling of bone matrix, and be used as a marker to evaluate bone resorption activity. Based on this, this effect example aims to explore the effect of the fermented ginseng hydrolyzate obtained in Example 1 on osteoclast differentiation. The specific scheme is as follows:
[0080] Bone marrow mononuclear cells were isolated from the femurs and tibias of 1-month-old C57BL / 6 mice and seeded into 24-well plates at a density of 1×10 5 cells / well. After overnight incubation, the culture medium was replaced with differentiation medium to induce the differentiation of bone marrow mononuclear cells into osteoclasts. The differentiation medium was α-MEM medium containing 10% fetal bovine serum and supplemented with M-CSF (25 ng / mL) and RANKL (25 ng / mL). Different concentrations of the fermented ginseng hydrolysate prepared in Example 1 (12.5, 25, 50, and 100 μg / mL) were added simultaneously when the differentiation medium was changed, and alendronate (1 μM) was used as a positive control drug. The differentiation medium was changed once on the 4th day, and TRAP staining was performed on the 7th day. The number of osteoclasts was observed and counted under a microscope according to the characteristics of osteoclasts. The statistical results are shown in Table 4. The characteristics of osteoclasts are cells with more than 3 nuclei and positive TRAP staining.
[0081] Table 4 Number of osteoclasts in different treatment groups
[0082]
[0083]
[0084] As shown in Table 3, fermented ginseng hydrolysates at different concentrations all had a significant effect of reducing osteoclasts, and when the concentration was 100 μg / mL, the effect of the fermented ginseng hydrolysate was better than that of the positive drug alendronate, indicating that the fermented ginseng hydrolysate of the present invention has the efficacy of inhibiting the differentiation of bone marrow mononuclear cells into osteoclasts.
[0085] Effect Example 3
[0086] Ovariectomized mice (OVX mice) are a classic animal model for studying postmenopausal osteoporosis. By surgically removing the ovaries of mice, the hormonal changes after menopause in women are simulated, especially the significant decrease in estrogen levels. These hormonal changes lead to increased bone resorption and decreased bone formation, resulting in reduced bone density and degradation of bone microstructure, ultimately leading to the occurrence of osteoporosis. On this basis, in this effect example, an OVX mouse model was constructed to evaluate the efficacy of the fermented ginseng hydrolysate obtained in Example 1 on osteoporosis. The specific protocol is as follows:
[0087] SPF-grade 6-week-old C57BL / 6 female mice were purchased from the Guangdong Provincial Center for Medical Experimental Animals (SCXK(Guangdong)2022-0002). The environmental temperature was 20-25°C, the humidity was 40% - 60%, and the daily light exposure was 12 h (7:00-19:00). They were fed ad libitum and allowed to drink water freely. The experiment was conducted when they reached 3 months of age.
[0088] The construction of the OVX model was as follows: mice were fasted but not watered 12 hours before the ovariectomy. The mice were anesthetized with isoflurane, fixed in a supine position, and the skin of the abdominal surgical area was disinfected with 75% alcohol. The skin and muscles were cut longitudinally, with an incision of about 0.5 cm, exposing the pink ovaries. The ovaries were removed after ligation of the junction between the uterus and the ovaries, and the muscles and skin were sutured layer by layer, and the mice were returned to a clean cage. The sham surgery only performed a ventral incision without removing the ovaries. After the operation, all mice were intraperitoneally injected with penicillin every other day to prevent infection, and the cages were changed every day. Subsequent experiments were performed one week later.
[0089] Ovariectomized mice were randomly divided into OVX model group, low-dose fermented ginseng hydrolysate (250 mg / kg) group, medium-dose fermented ginseng hydrolysate (500 mg / kg) group, high-dose fermented ginseng hydrolysate (1000 mg / kg) group, and 17β-estradiol positive drug group (10 μg / kg), with 5 mice in each group, and sham-operated mice were used as normal control group. Enzymatic fermented ginseng peptides were administered by gavage, and 17β-estradiol was administered by subcutaneous injection once a day for 2 consecutive months. After fasting for 12 hours after the last administration, the mice were euthanized, and the right hind limbs of the mice were scanned to determine the bone density and the number of trabeculae. The results are shown in Table 5.
[0090] Table 5 Bone density and trabecular number of mice in different treatment groups
[0091]
[0092] As shown in Table 4, compared with the normal group (sham operation), the bone density and trabecular number of the right hind limbs of the OVX model group mice were significantly reduced, indicating that the osteoporosis model was successfully constructed. In contrast, the fermented ginseng hydrolyzate can significantly improve the bone density and trabecular number reduced by removing the ovaries, and at a dose of 1000 mg / kg, its effect is better than that of the positive drug 17β-estradiol. The above results suggest that the fermented ginseng hydrolyzate provided by the present invention can resist osteoporosis caused by hormone changes and has a certain bone tissue protection effect.
[0093] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A ginseng peptide, characterized in that: The ginseng peptide comprises a characteristic peptide having an amino acid sequence of at least one of Leu-Tyr, Met-Met, Leu-Arg, Leu-Ala-Arg, Ser-Ala-Leu-Ala-Phe-Arg, Arg-Leu-Asp-Phe-Arg, Leu-Leu-Leu-Leu-Gly-His, Leu-Leu-Leu-Leu-Leu-Gly-His and Ala-Pro.
2. The ginseng peptide according to claim 1, characterized in that: The ginseng peptides include a characteristic peptide with the amino acid sequence of Leu-Tyr, a characteristic peptide of Met-Met, a characteristic peptide of Leu-Arg, a characteristic peptide of Leu-Ala-Arg, a characteristic peptide of Ser-Ala-Leu-Ala-Phe-Arg, a characteristic peptide of Arg-Leu-Asp-Phe-Arg, a characteristic peptide of Leu-Leu-Leu-Leu-Gly-His, a characteristic peptide of Leu-Leu-Leu-Leu-Leu-His-Gly and a characteristic peptide of Ala-Pro.
3. A fermented ginseng hydrolyzate, characterized in that: Comprising the ginseng peptide as described in claim 1 or 2.
4. The fermented ginseng hydrolyzate according to claim 3, characterized in that: The mass ratios of the characteristic peptide Leu-Tyr, characteristic peptide Met-Met, characteristic peptide Leu-Arg, characteristic peptide Leu-Ala-Arg, characteristic peptide Ser-Ala-Leu-Ala-Phe-Arg, characteristic peptide Arg-Leu-Asp-Phe-Arg, characteristic peptide Leu-Leu-Leu-Leu-Gly-His, characteristic peptide Leu-Leu-Leu-Leu-Leu-His-Gly and characteristic peptide Ala-Pro of ginseng peptides in the fermented ginseng hydrolysate are Leu-Tyr:Met-Met:Leu-Arg: Leu-Ala-Arg: Ser-Ala-Leu-Ala-Phe-Arg: Arg-Leu-Asp-Phe-Arg: Leu-Leu-Leu-Leu-Gly-His: Leu-Leu-Leu-Leu-Leu-Gly-H is: Ala-Pro=(49.6-52.1): (6.3-7.6): (7.5-8.8): (1.5-1.8): (18.1-19.5): (2.6-3.1): (1.4-1.6): (1.2-1.5): (7.8-8.0).
5. The method for preparing the fermented ginseng hydrolyzate according to claim 3, characterized in that: The following steps are involved: (1) mixing the fermented ginseng residue with water, adjusting the pH to 7.0-8.0, extracting at 45-55° C. for 30-40 min, adding protease, bathing at 45-55° C. for 4-5 h, centrifuging, and obtaining an enzymatic solution; (2) Drying the enzymatic hydrolyzate obtained in step (2) to obtain a fermented ginseng hydrolyzate containing ginseng peptides.
6. The preparation method according to claim 5, characterized in that: In step (1), the ratio of the fermented ginseng residue to water is fermented ginseng residue: water = 1 g: (25-30) mL.
7. The preparation method according to claim 5, characterized in that: In step (2), the type of protease includes at least one of papain, trypsin and alkaline protease.
8. The preparation method according to claim 5, characterized in that: In step (2), the amount of protease added is 0.75-0.80 mg of protease per 1 g of fermented ginseng residue, and the concentration of the protease is 1350-1400 U / mg.
9. Use of the ginseng peptide according to claim 1 or the fermented ginseng hydrolyzate according to claim 3 in the preparation of products for improving osteoporosis and its complications.
10. Use of the ginseng peptide according to claim 1 or the fermented ginseng hydrolyzate according to claim 3 in the preparation of a product for preventing osteoporosis and its complications.
Citation Information
Patent Citations
Composite polypeptide calcium powder and preparation method and application thereof
CN112262993A
Preparation method of ginseng zymolyte containing polypeptide polysaccharide
CN114158725A
Preparation method and application of fermentation liquor rich in ginseng rare saponin groups
CN116334147A
Ginseng peptide
CN116554271A
Ginseng-sourced active peptide, preparation method thereof and application of active peptide in intestinal injury protection
CN117186183A
